No, the Alzheimer cure for all is not for tomorrow
09 March 2023
At the end of February, the CMS said it is still not convinced the new class of Alzheimer’s drugs (first brought forward by Biogen, but being studied also by Roche and Eli Lilly) are “reasonable and necessary” for seniors.
Lecanemab (by Biogen/Eisai) is not the Alzheimer's "cure" it wants to be. Despite a slightly better clinical profile than Aduhelm (Biogen's previous drug), the CMS told the Alzheimer’s Association no “new evidence [..] meets the required criteria” to reconsider its reimbursement policy.
After Biogen and Roche, also Eli Lilly is attempting to find a cure using the same drug class, but it is unlikely to yield much better results. Alzheimer's disease is still a tough nut to crack, and investors should remain very cautious in the space. The annual $50bn Alzheimer's market is still far from having a functional drug.
This article is available to logged users.
Sign in or request a login.
This report has been produced by the organizational unit responsible for investment research (Research unit) of atonra Partners and sent to you by the company sales representatives.
As an internationally active company, atonra Partners SA may be subject to a number of provisions in drawing up and distributing its investment research documents. These regulations include the Directives on the Independence of Financial Research issued by the Swiss Bankers Association. Although atonra Partners SA believes that the information provided in this document is based on reliable sources, it cannot assume responsibility for the quality, correctness, timeliness or completeness of the information contained in this report.
The information contained in these publications is exclusively intended for a client base consisting of professionals or qualified investors. It is sent to you by way of information and cannot be divulged to a third party without the prior consent of atonra Partners. While all reasonable effort has been made to ensure that the information contained is not untrue or misleading at the time of publication, no representation is made as to its accuracy or completeness and it should not be relied upon as such.
Past performance is not indicative or a guarantee of future results. Investment losses may occur, and investors could lose some or all of their investment. Any indices cited herein are provided only as examples of general market performance and no index is directly comparable to the past or future performance of the Certificate.
It should not be assumed that the Certificate will invest in any specific securities that comprise any index, nor should it be understood to mean that there is a correlation between the Certificate’s returns and any index returns.
Any material provided to you is intended only for discussion purposes and is not intended as an offer or solicitation with respect to the purchase or sale of any security and should not be relied upon by you in evaluating the merits of investing inany securities.